Monopar Therapeutics Net Income
| MNPR Stock | USD 59.29 2.22 3.89% |
As of the 11th of February 2026, Monopar Therapeutics secures the Mean Deviation of 3.09, standard deviation of 4.12, and Risk Adjusted Performance of (0.08). In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Monopar Therapeutics, as well as the relationship between them. Please verify Monopar Therapeutics information ratio and kurtosis to decide if Monopar Therapeutics is priced some-what accurately, providing market reflects its recent price of 59.29 per share. Given that Monopar Therapeutics has information ratio of (0.14), we recommend you to check Monopar Therapeutics's last-minute market performance to make sure the company can sustain itself at a future point.
Monopar Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Monopar Therapeutics' valuation are provided below:There are over one hundred four available fundamental ratios for Monopar Therapeutics, which can be analyzed over time and compared to other ratios. Investors and active traders are advised to check Monopar Therapeutics' last-minute fundamental performance against the performance between 2010 and 2026 to make sure the trends are evolving in the right direction. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -14 M | -13.3 M | |
| Net Loss | -8.2 M | -8.6 M | |
| Net Loss | -14 M | -13.3 M | |
| Net Loss | (1.57) | (1.49) | |
| Net Income Per E B T | 1.12 | 1.09 |
Monopar | Net Income | Build AI portfolio with Monopar Stock |
Evaluating Monopar Therapeutics's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Monopar Therapeutics's fundamental strength.
Latest Monopar Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Monopar Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Monopar Therapeutics financial statement analysis. It represents the amount of money remaining after all of Monopar Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Monopar Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Monopar Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (15.59 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Monopar Net Income Regression Statistics
| Arithmetic Mean | (6,261,020) | |
| Coefficient Of Variation | (94.45) | |
| Mean Deviation | 5,139,725 | |
| Median | (4,125,987) | |
| Standard Deviation | 5,913,727 | |
| Sample Variance | 35T | |
| Range | 15.9M | |
| R-Value | (0.81) | |
| Mean Square Error | 13.1T | |
| R-Squared | 0.65 | |
| Significance | 0.000097 | |
| Slope | (942,863) | |
| Total Sum of Squares | 559.6T |
Monopar Net Income History
Other Fundumenentals of Monopar Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Monopar Therapeutics Net Income component correlations
Monopar Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Monopar Therapeutics is extremely important. It helps to project a fair market value of Monopar Stock properly, considering its historical fundamentals such as Net Income. Since Monopar Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Monopar Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Monopar Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Can Biotechnology industry sustain growth momentum? Does Monopar have expansion opportunities? Factors like these will boost the valuation of Monopar Therapeutics. Expected growth trajectory for Monopar significantly influences the price investors are willing to assign. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Monopar Therapeutics demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
The market value of Monopar Therapeutics is measured differently than its book value, which is the value of Monopar that is recorded on the company's balance sheet. Investors also form their own opinion of Monopar Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Monopar Therapeutics' true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because Monopar Therapeutics' market value can be influenced by many factors that don't directly affect Monopar Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Monopar Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Monopar Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Monopar Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Monopar Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Monopar Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Monopar Therapeutics.
| 11/13/2025 |
| 02/11/2026 |
If you would invest 0.00 in Monopar Therapeutics on November 13, 2025 and sell it all today you would earn a total of 0.00 from holding Monopar Therapeutics or generate 0.0% return on investment in Monopar Therapeutics over 90 days. Monopar Therapeutics is related to or competes with Compass Therapeutics, 4D Molecular, Bicycle Therapeutics, Fulcrum Therapeutics, Gossamer Bio, Lexicon Pharmaceuticals, and Omeros. Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatm... More
Monopar Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Monopar Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Monopar Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.14) | |||
| Maximum Drawdown | 21.47 | |||
| Value At Risk | (8.57) | |||
| Potential Upside | 5.46 |
Monopar Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Monopar Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Monopar Therapeutics' standard deviation. In reality, there are many statistical measures that can use Monopar Therapeutics historical prices to predict the future Monopar Therapeutics' volatility.| Risk Adjusted Performance | (0.08) | |||
| Jensen Alpha | (0.51) | |||
| Total Risk Alpha | (0.91) | |||
| Treynor Ratio | (1.31) |
Monopar Therapeutics February 11, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.08) | |||
| Market Risk Adjusted Performance | (1.30) | |||
| Mean Deviation | 3.09 | |||
| Coefficient Of Variation | (873.59) | |||
| Standard Deviation | 4.12 | |||
| Variance | 16.99 | |||
| Information Ratio | (0.14) | |||
| Jensen Alpha | (0.51) | |||
| Total Risk Alpha | (0.91) | |||
| Treynor Ratio | (1.31) | |||
| Maximum Drawdown | 21.47 | |||
| Value At Risk | (8.57) | |||
| Potential Upside | 5.46 | |||
| Skewness | (0.27) | |||
| Kurtosis | 0.8111 |
Monopar Therapeutics Backtested Returns
Monopar Therapeutics has Sharpe Ratio of -0.14, which conveys that the firm had a -0.14 % return per unit of risk over the last 3 months. Monopar Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Monopar Therapeutics' Standard Deviation of 4.12, mean deviation of 3.09, and Risk Adjusted Performance of (0.08) to check out the risk estimate we provide. The company secures a Beta (Market Risk) of 0.37, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Monopar Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Monopar Therapeutics is expected to be smaller as well. At this point, Monopar Therapeutics has a negative expected return of -0.61%. Please make sure to verify Monopar Therapeutics' total risk alpha, kurtosis, as well as the relationship between the Kurtosis and market facilitation index , to decide if Monopar Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.26 |
Poor predictability
Monopar Therapeutics has poor predictability. Overlapping area represents the amount of predictability between Monopar Therapeutics time series from 13th of November 2025 to 28th of December 2025 and 28th of December 2025 to 11th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Monopar Therapeutics price movement. The serial correlation of 0.26 indicates that nearly 26.0% of current Monopar Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.26 | |
| Spearman Rank Test | 0.43 | |
| Residual Average | 0.0 | |
| Price Variance | 22.64 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Monopar Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Monopar Therapeutics reported net income of (15.59 Million). This is 104.57% lower than that of the Biotechnology sector and 122.25% lower than that of the Health Care industry. The net income for all United States stocks is 102.73% higher than that of the company.
Monopar Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Monopar Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Monopar Therapeutics could also be used in its relative valuation, which is a method of valuing Monopar Therapeutics by comparing valuation metrics of similar companies.Monopar Therapeutics is currently under evaluation in net income category among its peers.
Monopar Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Monopar Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Monopar Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Monopar Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Monopar Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Monopar Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Monopar Therapeutics' value.| Shares | Northern Trust Corp | 2025-06-30 | 31.8 K | Ubs Group Ag | 2025-06-30 | 21.9 K | Millennium Management Llc | 2025-06-30 | 14.8 K | Charles Schwab Investment Management Inc | 2025-06-30 | 13.2 K | Bank Of New York Mellon Corp | 2025-06-30 | 8.9 K | Susquehanna International Group, Llp | 2025-06-30 | 8.4 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 7.9 K | Barclays Plc | 2025-06-30 | 7.3 K | Citadel Advisors Llc | 2025-06-30 | 6.2 K | Hhg Plc | 2025-06-30 | 1.2 M | Adage Capital Partners Gp Llc | 2025-06-30 | 599.2 K |
Monopar Fundamentals
| Return On Equity | -0.27 | ||||
| Return On Asset | -0.18 | ||||
| Current Valuation | 245.79 M | ||||
| Shares Outstanding | 6.68 M | ||||
| Shares Owned By Insiders | 21.69 % | ||||
| Shares Owned By Institutions | 68.41 % | ||||
| Number Of Shares Shorted | 1.28 M | ||||
| Price To Earning | (35.82) X | ||||
| Price To Book | 2.75 X | ||||
| EBITDA | (16.16 M) | ||||
| Net Income | (15.59 M) | ||||
| Cash And Equivalents | 16.46 M | ||||
| Cash Per Share | 1.29 X | ||||
| Total Debt | 5.25 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 7.61 X | ||||
| Book Value Per Share | 21.25 X | ||||
| Cash Flow From Operations | (6.4 M) | ||||
| Short Ratio | 4.06 X | ||||
| Earnings Per Share | (3.96) X | ||||
| Target Price | 112.0 | ||||
| Number Of Employees | 14 | ||||
| Beta | 1.57 | ||||
| Market Capitalization | 381.38 M | ||||
| Total Asset | 60.29 M | ||||
| Retained Earnings | (75.79 M) | ||||
| Working Capital | 55.04 M | ||||
| Current Asset | 11.55 M | ||||
| Current Liabilities | 598.26 K | ||||
| Net Asset | 60.29 M |
About Monopar Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Monopar Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Monopar Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Monopar Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Monopar Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Monopar Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Monopar Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Monopar Stock
Moving against Monopar Stock
| 0.79 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.58 | DSGN | Design Therapeutics | PairCorr |
| 0.49 | ENGN | enGene Holdings Common | PairCorr |
| 0.42 | 63E | ONWARD MEDICAL BV | PairCorr |
| 0.37 | KYTX | Kyverna Therapeutics | PairCorr |
The ability to find closely correlated positions to Monopar Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Monopar Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Monopar Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Monopar Therapeutics to buy it.
The correlation of Monopar Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Monopar Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Monopar Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Monopar Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Monopar Stock Analysis
When running Monopar Therapeutics' price analysis, check to measure Monopar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monopar Therapeutics is operating at the current time. Most of Monopar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Monopar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monopar Therapeutics' price. Additionally, you may evaluate how the addition of Monopar Therapeutics to your portfolios can decrease your overall portfolio volatility.